Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + PE vs PE in Neoadjuvant HR+/HER2- Breast Cancer
NCT06967103Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of QL1706 in breast cancer (2 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Pathological Complete Response up to 24 weeks and Pathological Complete Response in PDL1 positive subgroup up to 24 weeks. Started Sep 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06967103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967103.